9 314 person-years of follow-up were accumulated. At inclusion, patients were 61.5 year-old on average (standard deviation (SD): 10.7) and 54.6% were males. Classified by CV risk categories were for primary prevention 29.3% low, 32.4% moderate and 11.4% high, and 26.9% secondary prevention.
Type of ezetimibe exposure at inclusion was 33.1% monotherapy, 13.2% ezetimibe added to a statin, and 53.7% fixed association ezetimibe – simvastatin. Exposure to ezetimibe has been very stable during follow-up of the cohort with treatment interruption rate of 12.5 per 100 person-years of followup. LDL-C was 4.1mmol/L (SD: 1.1) at baseline and decreased by 23.8% (SD: 28.8) in the first 12 months, reaching –27.3% (SD: 28.3) at 48 months. Adjusting for baseline clinical characteristics and risk factors, interruption of lipid lowering treatment at least once during the follow-up was associated with a lower probability for the LDL-C to progress to the lower tertile (OR: 0.38, 95% confidence interval: 0.31 – 0.45). In this population with incident exposure to ezetimibe LDL-C decreased by one quarter in the first year and remained stable over the four-year follow-up.